121 related articles for article (PubMed ID: 38200649)
1. Thrombocytopenia and disease outcomes in a cohort of patients with systemic lupus erythematosus. A post hoc analysis of the COMOSLE-EGYPT study.
Mohamed SS; Gamal SM; Mokbel A; Alkamary AK; Siam I; Soliman A; Elgengehy FT
Int J Rheum Dis; 2024 Jan; 27(1):e15016. PubMed ID: 38200649
[TBL] [Abstract][Full Text] [Related]
2. Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study.
Sobhy N; Ezzat Y; Gamal SM; Ghoniem SA; Nasr SS; Badran S; Soliman A; Fouad NA
Clin Rheumatol; 2024 Mar; 43(3):985-992. PubMed ID: 38198114
[TBL] [Abstract][Full Text] [Related]
3. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Chock YP; Moulinet T; Dufrost V; Erkan D; Wahl D; Zuily S
Autoimmun Rev; 2019 Nov; 18(11):102395. PubMed ID: 31520800
[TBL] [Abstract][Full Text] [Related]
4. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Riancho-Zarrabeitia L; Martínez-Taboada V; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Fernández-Nebro A; Calvo-Alén J; Menor-Almagro R; Tomero-Muriel E; Uriarte-Isacelaya E; Botenau A; Andres M; Freire-González M; Santos Soler G; Ruiz-Lucea E; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez-García J; Expósito L; Hernández-Beriaín JA; Horcada L; Aurrecoechea E; Pego-Reigosa JM
Lupus; 2020 Oct; 29(12):1556-1565. PubMed ID: 32807021
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.
Brunner HI; Silverman ED; To T; Bombardier C; Feldman BM
Arthritis Rheum; 2002 Feb; 46(2):436-44. PubMed ID: 11840446
[TBL] [Abstract][Full Text] [Related]
7. Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study.
Gamal SM; Mokbel A; Niazy MH; Elgengehy FT; Elsaid NY; Fouad NA; Sobhy N; Tantawy M; Mohamed SS; Ghaleb RM; Abdelaleem EA; El-Zorkany B
Chronic Illn; 2023 Dec; 19(4):791-803. PubMed ID: 36373605
[TBL] [Abstract][Full Text] [Related]
8. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.
Unlu O; Erkan D; Barbhaiya M; Andrade D; Nascimento I; Rosa R; Banzato A; Pengo V; Ugarte A; Gerosa M; Ji L; Efthymiou M; Branch DW; de Jesus GR; Tincani A; Belmont HM; Fortin PR; Petri M; Rodriguez E; Pons-Estel GJ; Knight JS; Atsumi T; Willis R; Zuily S; Tektonidou MG;
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):134-141. PubMed ID: 29669399
[TBL] [Abstract][Full Text] [Related]
10. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies.
Gheita TA; Abaza NM; Hammam N; Mohamed AAA; El-Gazzar II; Eissa AH
Lupus; 2018 Jun; 27(7):1081-1087. PubMed ID: 29460701
[TBL] [Abstract][Full Text] [Related]
11. Real-Time PCR of cytomegalovirus and Epstein-Barr virus in adult Egyptian patients with systemic lupus erythematosus.
Mohamed AE; Hasen AM; Mohammed GF; Elmaraghy NN
Int J Rheum Dis; 2015 May; 18(4):452-8. PubMed ID: 24341363
[TBL] [Abstract][Full Text] [Related]
12. Comparison between disease onset patterns of Egyptian juvenile and adult systemic lupus erythematosus (single centre experience).
Abdel-Nabi HH; Abdel-Noor RA
Lupus; 2018 May; 27(6):1039-1044. PubMed ID: 29460702
[TBL] [Abstract][Full Text] [Related]
13. Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients-a multicenter retrospective cohort.
Medhat BM; Behiry ME; Sobhy N; Farag Y; Marzouk H; Mostafa N; Khalifa I; Elkhalifa M; Eissa BM; Hassan EHE
Clin Rheumatol; 2020 Feb; 39(2):435-442. PubMed ID: 31758421
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study.
Afifi N; El Bakry SA; Mohannad N; Bassyouni IH; Elezz NFA; El-Shazly R; Hussein SA
Curr Rheumatol Rev; 2021; 17(2):222-231. PubMed ID: 33243127
[TBL] [Abstract][Full Text] [Related]
15. Antiphospholipid antibodies in pediatric systemic lupus erythematosus.
Seaman DE; Londino AV; Kwoh CK; Medsger TA; Manzi S
Pediatrics; 1995 Dec; 96(6):1040-5. PubMed ID: 7491218
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus.
Jallouli M; Frigui M; Marzouk S; Snoussi M; Kechaou M; Kaddour N; Masmoudi H; Elloumi M; Bahloul Z
Lupus; 2012 May; 21(6):682-7. PubMed ID: 22354537
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups.
Lopes SRM; Gormezano NWS; Gomes RC; Aikawa NE; Pereira RMR; Terreri MT; Magalhães CS; Ferreira JC; Okuda EM; Sakamoto AP; Sallum AME; Appenzeller S; Ferriani VPL; Barbosa CM; Lotufo S; Jesus AA; Andrade LEC; Campos LMA; Bonfá E; Silva CA;
Lupus; 2017 Aug; 26(9):996-1001. PubMed ID: 28134038
[TBL] [Abstract][Full Text] [Related]
19. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
[TBL] [Abstract][Full Text] [Related]
20. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Riancho-Zarrabeitia L; Martínez-Taboada VM; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Mena Vázquez N; Calvo-Alén J; Menor Almagro R; Tomero Muriel E; Uriarte Isacelaya E; Boteanu A; Andres M; Freire González M; Santos Soler G; Ruiz-Lucea ME; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez J; Expósito L; Hernández Beriaín JA; Horcada L; Aurrecoechea E; Pego Reigosa JM
Clin Exp Rheumatol; 2021; 39(3):555-563. PubMed ID: 32828148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
